Investigation of whether the Glasgow Prognostic Score is a predictor of response to nivolumab in combination with low-dose ipilimumab as first-line therapy in patients with advanced gastric or esophagogastric junction cancer with MSI-H(WJOG18624G)

Investigation of whether the Glasgow Prognostic Score is a predictor of response to nivolumab in combination with low-dose ipilimumab as first-line therapy in patients with advanced gastric or esophagogastric junction cancer with MSI-H(WJOG18624G) - GPS evaluation in NO LIMIT study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055039

Enrollment

Registered

2024-07-22

Start date

2024-09-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced gastric or oesophagogastric junction cancer with MSI-H

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Enrolled in the NO LIMIT trial and treated with NIVO+IPI

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To collect CRP values at screening in patients with advanced gastric or oesophagogastric junction cancer with MSI-H who participated in the WJOG13320G/CA209-7W7 (hereafter NO LIMIT) study and calculate the Glasgow Prognostic Score	—

Countries

Japan

Contacts

Public ContactNaoki Ishizuka

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results